fig2

Figure 2. EEF1A2 plays a role in the development of lung cancer brain metastasis (LCBM) and is linked to poor outcomes in lung cancer patients. (A and B) the GO analysis of (A) upregulated and (B) downregulated mRNAs when comparing LCBM to LC groups. (C and D) the KEGG pathway analysis of (C) upregulated and (D) downregulated mRNAs between LCBM and LC groups. (E) CeRNA network incorporating the top 10 upregulated mRNAs. (F) the expression levels of EEF1A2 in tumor tissues (T) vs. adjacent normal tissues (N) from LUAD and LUSC patients based on TCGA and GTEx data. (G) EEF1A2 expression across stages I-IV in LUAD and LUSC patients according to TCGA and GTEx datasets. (H) Kaplan-Meier survival curves for overall survival (OS) of LUAD patients with high or low EEF1A2 expression, utilizing data from the TCGA, GEO, and EGA databases. Data are presented as means ± S.D.; *P < 0.05.